Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer
Condition(s):HER2-positive Breast Cancer; Early-stage Breast CancerLast Updated:September 13, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):HER2-positive Breast Cancer; Early-stage Breast CancerLast Updated:September 13, 2023Recruiting
Condition(s):Neoadjuvant Treatment for HER2-positive, ER-positive Breast CancerLast Updated:April 26, 2021Not yet recruiting
Condition(s):Metastatic Breast CancerLast Updated:July 9, 2018Completed
Condition(s):Breast CancerLast Updated:March 2, 2022Unknown status
Condition(s):HER2+ Advanced Breast Cancer Patients Progressing on TKI TherapyLast Updated:October 3, 2022Not yet recruiting
Condition(s):Non Small Cell LungLast Updated:March 29, 2017Unknown status
Condition(s):Metastatic Breast CancerLast Updated:May 6, 2023Active, not recruiting
Condition(s):Breast CancerLast Updated:September 14, 2023Recruiting
Condition(s):Breast Cancer Invasive; Hormone-receptor-positive Breast Cancer; HER2 Low Breast Carcinoma; Early-stage Breast CancerLast Updated:January 25, 2024Recruiting
Condition(s):Breast Cancer; HER2 Positive; Combination ChemotherapyLast Updated:November 5, 2019Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.